MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 10-29-2024
10x Genomics Revenue 2011-2026 | TXG
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue 10x Genomics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 619 M | 516 M | 490 M | 299 M | 246 M | 146 M | 71.1 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 619 M | 71.1 M | 341 M |
Quarterly Revenue 10x Genomics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152 M | 153 M | 141 M | 154 M | 147 M | 134 M | - | - | 115 M | 114 M | - | 125 M | 116 M | 106 M | - | 71.8 M | 42.9 M | 71.9 M | 75.3 M | 61.2 M | 55.8 M | 53.6 M | 50.6 M | 36.6 M | 31.7 M | 27.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | 27.4 M | 92.5 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Accolade
ACCD
|
170 M | - | 0.29 % | $ 206 M |  USA |
 |
Change Healthcare
CHNG
|
3.09 B | - | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B | USA |
 |
American Well Corporation
AMWL
|
249 M | $ 5.63 | -2.26 % | $ 90.3 M | USA |
 |
HealthStream
HSTM
|
292 M | $ 21.23 | 1.24 % | $ 645 M | USA |
 |
Computer Programs and Systems
CPSI
|
339 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
NextGen Healthcare
NXGN
|
557 M | - | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
623 M | - | - | $ 3.37 B | USA |
 |
Premier
PINC
|
263 M | - | - | $ 2.33 B | USA |
 |
Omnicell
OMCL
|
1.11 B | $ 34.94 | 1.39 % | $ 1.61 B | USA |
 |
Phreesia
PHR
|
356 M | $ 11.28 | - | $ 615 M | USA |
 |
OptimizeRx Corporation
OPRX
|
71.5 M | $ 7.18 | 5.9 % | $ 123 M | USA |
 |
Evolent Health
EVH
|
382 M | $ 2.27 | 0.89 % | $ 213 M | USA |
 |
Schrödinger
SDGR
|
256 M | $ 11.4 | -1.47 % | $ 837 M | USA |
 |
MTBC
MTBC
|
120 M | - | -0.58 % | $ 51.7 M | USA |
 |
Teladoc Health
TDOC
|
2.53 B | $ 5.57 | 2.77 % | $ 982 M | USA |
 |
GoodRx Holdings
GDRX
|
792 M | $ 2.06 | 0.98 % | $ 795 M | USA |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
SCWorx Corp.
WORX
|
2.99 M | $ 0.13 | 1.5 % | $ 190 K | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
Akerna Corp.
KERN
|
20.5 M | - | - | $ 161 M | USA |
 |
Zhongchao
ZCMD
|
16.3 M | $ 1.8 | -0.55 % | $ 9.37 M |  China |
 |
Allscripts Healthcare Solutions
MDRX
|
1.5 B | - | -10.39 % | $ 886 M | USA |
 |
Health Catalyst
HCAT
|
311 M | $ 1.1 | 0.46 % | $ 76.9 M | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
HealthEquity
HQY
|
1.31 B | $ 82.47 | 0.45 % | $ 7.1 B | USA |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
Progyny
PGNY
|
298 M | $ 17.75 | -1.66 % | $ 1.52 B | USA |
 |
So-Young International
SY
|
-1.52 M | $ 3.19 | 9.62 % | $ 253 M | China |
 |
Veeva Systems
VEEV
|
3.2 B | $ 178.11 | -0.56 % | $ 29.2 B | USA |